Hypertension Pipeline Summary

DelveInsight’s, “Hypertension - Pipeline Insight, 2026” report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Hypertension: Understanding

Hypertension: Overview

Hypertension, commonly known as high blood pressure, is a chronic medical condition characterized by elevated pressure in the arteries, which can lead to serious health complications if left untreated. It is classified into primary hypertension, which has no identifiable cause and often develops gradually over many years, and secondary hypertension, which results from an underlying condition, such as kidney disease or hormonal disorders. Hypertension is a major risk factor for cardiovascular diseases, including heart attack and stroke, as well as kidney damage and vision loss.

Hypertension, often referred to as the "silent killer," may not present noticeable signs or symptoms, particularly in its early stages, which makes regular monitoring essential. When symptoms do occur, they can include headaches, dizziness, shortness of breath, nosebleeds, and palpitations. In severe cases, individuals may experience blurred vision, chest pain, or fatigue, indicating potential damage to the heart or other organs. It's important to note that many people with hypertension may remain asymptomatic for years, underscoring the need for routine blood pressure checks to detect the condition early and prevent serious health complications.

The pathology of hypertension involves complex interactions between genetic, environmental, and physiological factors that lead to sustained elevations in arterial blood pressure. Central to this process is the dysfunction of the vascular system, particularly the endothelium, which regulates vascular tone and blood flow. In hypertension, factors such as oxidative stress, inflammation, and abnormal production of vasoactive substances (e.g., endothelin and nitric oxide) contribute to endothelial dysfunction and increased vascular resistance. Additionally, neurohumoral mechanisms, including the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system activation, play crucial roles in promoting vasoconstriction and fluid retention.

The diagnosis of hypertension primarily involves measuring blood pressure using a sphygmomanometer, with readings taken at multiple visits to confirm persistently elevated levels. According to the American College of Cardiology and the American Heart Association, hypertension is diagnosed when blood pressure readings consistently exceed 130/80 mm Hg. Alongside blood pressure measurements, healthcare providers may conduct a thorough medical history, physical examination, and various laboratory tests to assess potential underlying causes and complications, such as kidney function tests, electrolyte levels, and lipid profiles

The treatment of hypertension typically involves a multifaceted approach, combining lifestyle modifications and pharmacological interventions to effectively manage blood pressure levels and reduce the risk of cardiovascular complications. Lifestyle changes, such as adopting a heart-healthy diet rich in fruits, vegetables, whole grains, and low-fat dairy (e.g., the DASH diet), maintaining a healthy weight, engaging in regular physical activity, and limiting alcohol intake and sodium consumption, are essential first steps.

"Hypertension- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hypertension pipeline landscape is provided which includes the disease overview and Hypertension treatment guidelines. The assessment part of the report embraces, in depth Hypertension commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypertension collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Hypertension R&D. The therapies under development are focused on novel approaches to treat/improve Hypertension.

Hypertension Emerging Drugs Chapters

This segment of the Hypertension report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hypertension Emerging Drugs

• Seralutinib: Gossamer Bio/ Chiesi USA, Inc.

Seralutinib is an inhaled medication designed to treat pulmonary arterial hypertension (PAH). It functions as an antagonist of several receptors, including platelet-derived growth factor receptors (PDGFR? and PDGFR?), colony-stimulating factor 1 receptor (CSF1R), and c-KIT. This multi-target approach aims to mitigate the inflammatory and proliferative pathways that contribute to pulmonary vascular remodeling associated with PAH. Currently, the drug is in the Phase III stage of its development for the treatment of Pulmonary Arterial Hypertension.

• Zilebesiran: Alnylam Therapeutics/ Roche

Zilebesiran is an investigational, long-acting small interfering RNA (siRNA) therapeutic designed to provide sustained blood pressure control by targeting the liver-produced precursor of angiotensin II. Zilebesiran acts through the RNA interference (RNAi) mechanism by specifically degrading messenger RNA (mRNA) encoding angiotensinogen (AGT) in hepatocytes, thereby markedly reducing circulating angiotensinogen levels. This suppresses the renin-angiotensin-aldosterone system (RAAS), leading to reduced formation of angiotensin I and angiotensin II, decreased vasoconstriction and aldosterone secretion, and ultimately lower blood pressure. Its long duration of action enables prolonged antihypertensive effects with infrequent dosing, making it a promising therapy for improving blood pressure control and treatment adherence. Currently, the drug is in the Phase III stage of its development for the treatment of Pulmonary Arterial Hypertension.

• LAM-001: Quince Therapeutics

LAM-001 is an investigational therapeutic which utilizes company's proprietary AIDE (Autologous Intracellular Drug Encapsulation) platform to deliver rapamycin (sirolimus) directly into patients' red blood cells, enabling sustained intracellular drug release while minimizing systemic exposure. Rapamycin inhibits the mammalian target of rapamycin (mTOR) signaling pathway, which is involved in vascular remodeling, inflammation, and smooth muscle cell proliferation. By modulating mTOR activity, LAM-001 is intended to improve vascular function and reduce pathological processes that contribute to elevated blood pressure, offering the potential for durable antihypertensive effects with an improved safety profile. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Hypertension.

• GSK6792070: GSK plc.

GSK6792070 is an investigational therapeutic being developed by GSK plc for the treatment of hypertension. It is a small interfering RNA (siRNA) therapy designed to achieve long-lasting blood pressure control by selectively targeting angiotensinogen (AGT), a key upstream component of the renin-angiotensin-aldosterone system (RAAS). Through the RNA interference (RNAi) mechanism, GSK6792070 degrades AGT messenger RNA (mRNA) in the liver, leading to reduced angiotensinogen production and decreased generation of angiotensin II. This suppresses RAAS activity, resulting in reduced vasoconstriction, lower aldosterone secretion, and sustained reductions in blood pressure, with the potential for infrequent dosing and improved treatment adherence. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Hypertension.

Further product details are provided in the report……..

Hypertension: Therapeutic Assessment

This segment of the report provides insights about the different Hypertension drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Hypertension

There are approx. 100+ key companies which are developing the therapies Hypertension. The companies which have their Hypertension drug candidates in the most advanced stage, i.e. Phase III include, Gossamer Bio, Chiesi USA, Inc., and others.

• Phases

DelveInsight’s report covers around 110+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hypertension: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hypertension therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypertension drugs.

Hypertension Report Insights

• Hypertension Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hypertension Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hypertension drugs?
• How many Hypertension drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hypertension?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hypertension therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hypertension and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Gossamer Bio
• Chiesi USA, Inc.
• Alnylam Therapeutics
• Roche
• Quince Therapeutics
• GSK plc.
• CalciMedica
• Suzhou Sanegene Bio Inc.
• Innovent Biologics, Inc.
• Insmed Incorporated
• Novartis Pharmaceuticals
• Vascarta
• NS Pharma, Inc.
• Regeneron Pharmaceuticals
• Apollo Therapeutics
• 35Pharma Inc.
• Guangzhou Magpie Pharmaceuticals Co., Ltd.
• Vanda Pharmaceuticals
• ADARx Pharmaceuticals, Inc.

Key Products

• Seralutinib
• Zilebesiran
• LAM-001
• GSK6792070
• CM5480
• SGB 3908
• Treprostinil Palmitil
• QCZ 484
• VAS-101
• NS-863
• REGN13335
• APL-9796
• HS235
• MN-08
• Iloperidone
• ADX-850